D-0874-2022 Class II Terminated
FDA drug recall D-0874-2022 was initiated by Pfizer Inc. on Apr 22, 2022 and is designated Class II. Reason for recall: CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits. The recall status is terminated (terminated Oct 5, 2023). Affected quantity: 8346 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- May 25, 2022
- Initiation Date
- Apr 22, 2022
- Termination Date
- Oct 5, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 8346 bottles
Product Description
Accupril (Quinapril HCl Tablets) 40 mg, 90 Tablets, Rx only NDC 0071-0535-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017
Reason for Recall
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
Distribution Pattern
Nationwide and Puerto Rico
Code Information
Lots: DX6031 Exp. MAR 31 2023; CK6260 Exp. MAY 31 2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0874-2022
- openFDA file date
- Oct 23, 2026
- Loaded by RegDataLab
- Oct 26, 2026